Terray Therapeutics has launched EMMI Predict: TerraBind, a universal potency prediction model that achieves 20% higher accuracy than leading open-source models whilst running 26 times faster, reducing inference costs by 96%. The model supports Terray's drug discovery platform, which combines experimentation with machine intelligence. TerraBind uses coarse-grained structural representations instead of computationally intensive diffusion processes, eliminating the diffusion module entirely whilst maintaining accuracy. In benchmarks, TerraBind outperformed Boltz-2 with 16% higher Pearson correlation on CASP16 and 20% better performance across 18 internal drug discovery targets. The model leverages Terray's dataset of 14 billion unique target-molecule measurements. Terray has raised $295 million and collaborates with Bristol Myers Squibb, Gilead and Odyssey Therapeutics on drug development programmes.

Terray Therapeutics expands Board of Directors with appointment of biotechnology leader Wendy Young, Ph.D.